Achiko AG Announces Corporate Update Webcast
16. November 2022 10:38 ET
|
Achiko AG
ZURICH, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”), a healthcare technology company that is developing new...
Achiko AG Reports First Half to June 30, 2022 Results and Provides Corporate Update as of September 30, 2022
03. Oktober 2022 07:33 ET
|
Achiko AG
Achiko reports an EBITDA loss of USD $1.9 million, compared to an EBITDA loss of USD $4.6 million for the six months ending June 30, 2021.Focal points of the first half year were completion of a major...
Achiko Secures $1.3 Million Financing with Strategic Investors Buranto AG and Negma Group
25. Mai 2022 07:30 ET
|
Achiko AG
Buranto AG Provided a USD$260,000 (CHF 250,000) Loan Facility and Existing Strategic Investor Negma Group Provided a USD$1.04 Million (CHF 1.0 Million) Loan FacilityDerek Brandt, Co-owner of Buranto...
AptameX Production and Commercialization Update
28. April 2022 08:15 ET
|
Achiko AG
Company has commenced shipping and will book first sales in May 2022Reorganized production line able to meet stronger than expected demand for Achiko AG’s innovative DNA aptamer saliva-based rapid...
Achiko AG Signs Major Marketing and Sales Agreement with World’s Largest Islamic Association for its AptameX Covid-19 Rapid Test
20. April 2022 07:45 ET
|
Achiko AG
Signed major deal with Pengurus Wilayah Nahdlatul Ulama DKI Jakarta, for the use of Covid-19 test AptameX in general assemblies and activities. Located primarily in Indonesia, Nahdlatul Ulama is the...
Achiko Secures up to USD$12.6 Million Equity and Debt Financing Lines with RiverFort Over Three Years
20. April 2022 07:30 ET
|
Achiko AG
ZURICH, Switzerland, April 20, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) announces the...
Achiko AG Production and Sales Update
03. März 2022 07:30 ET
|
Achiko AG
Unique Chemistry with DNA Aptamers Completing Pre-Sales Validation TestingCompleting Pre-Sales Validation Testing in Indonesia ZURICH, Switzerland, March 03, 2022 (GLOBE NEWSWIRE) -- Ad...
Achiko AG Research Paper and Commercialization Update
14. Februar 2022 07:30 ET
|
Achiko AG
Calibration study results now available in draft paper on medRxiv, a preprint platform for health sciences, as “DNA Aptamer Gold Nanoparticle Colorimetric Diagnostic Test Kit of Saliva Samples for...
Achiko AG Announces Feature Article on “How We Get Back to Normal” with its AptameX™ Covid-19 Rapid Test Technology
18. Januar 2022 07:30 ET
|
Achiko AG
ZURICH, Switzerland, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) is pleased to announce a feature article in The Jakarta Post:...
Achiko AG Reports Breakthrough Calibration Results for its AptameX™ Covid-19 Rapid Test Technology
14. Januar 2022 07:30 ET
|
Achiko AG
AptameX™ Covid-19 rapid calibration successfully classified 100% of results indicatinga likely > 97% Sensitivity and > 97% Specificity result in the first-generation test kits.Results were...